ANI Pharmaceuticals (ANIP)

[Just the facts maam]

In fairness to ART, from 2013 to 2018, he managed to find value and growth and not over pay for assets. Which a number of companies did during this period, and paid dearly when the FDA increased the rate of ANDA approvals and the purchasing consortiums squeeze the profits. The margins kept getting squeezed. He also acquired Corti, but was maybe over his head in getting it approved. That being said, Lalwani did have the benefit of a CRL to help get it across finish line.